Read the overview of a policy brief about patented medicine prices review board provided by HealthCareCAN.
- PMPRB’s new draft guidelines describe how it plans to bring down the costs of patented medicines based on new regulations published in Summer 2019.
- More expensive drugs, or those with larger markets will have prices regulated based on cost per quality-adjusted life year (QALY). QALY thresholds are slightly more generous than in the UK, but somewhat less so than in the US, when they are used at all.
- Price reductions based on the tests described by the new guidelines are likely to be significant.
- Patent-holders may see the new guidelines as a penalty for commercial success and either disinvest in clinical trials for large-market medicines, or delay market entry for new medicines.
- Delayed market entry is very likely in the short term, irrespective of how patent-holders respond.
For more information about the brief please contact HealthCareCAN’s Director of Communications and Member Services, Steve Wharry at 613-241-8005, ext. 205.
